FTC demands Boston Scientific divest business amid $4.2bn deal

08-08-2019

Sarah Morgan

FTC demands Boston Scientific divest business amid $4.2bn deal

Pavel Kapysh / Shutterstock.com

The US Federal Trade Commission is requiring medical device maker Boston Scientific to divest business, as part of a settlement resolving antitrust charges related to its acquisition of UK-based healthcare company BTG.


Boston Scientific, BTG, FTC, antitrust, mergers & acquisitions, medical device manufacture, healthcare, oncology, drug eluting beads, competition

More on this story

Boston Scientific acquires BTG for $4.2bn
20-11-2018

LSIPR